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Me
GeOBJECTIVES This study sought to evaluate procedural and clinical outcomes among patients undergoing chronic total
occlusion (CTO) percutaneous coronary intervention (PCI) using contemporarymethods and everolimus-eluting stents (EES).
BACKGROUND Limited studies have detailed the procedural and late-term safety and efﬁcacy of CTO revascularization
among multiple centers applying modern techniques and with newer-generation drug-eluting stents.
METHODS Among 20 centers, 250 consecutive patients were enrolled for attempted CTO PCI. Procedural and in-
hospital clinical outcomes were examined in addition to the 1-year primary endpoint of death, myocardial infarction,
and target lesion revascularization (major adverse cardiac events [MACE]).
RESULTS Demographic, lesion, and procedural characteristics included prior bypass surgery: 9.9%; diabetes: 40.1%;
lesion length: 36.1  18.5 mm; and stent length: 51.7  27.2 mm. Procedural success, deﬁned as guidewire recanalization
with no in-hospital MACE, was 96.4%. Success with antegrade-only methods was 97.9% and 86.2% by retrograde/
combined methods, respectively. Compared with a pre-speciﬁed performance goal derived from 6 prior CTO drug-eluting
stent trials (1-year MACE: 24.4%), treatment with EES was associated with signiﬁcantly lower composite adverse events
for both intent-to-treat (18.5%, 1-sided upper conﬁdence interval: 23.4%, p ¼ 0.025) and per-protocol populations
(8.2%, 1-sided upper conﬁdence interval: 12.3%, p < 0.0001). Target lesion revascularization at 1 year was 6.3%. Dual
antiplatelet therapy adherence was 53.9% at 1 year, yet subacute deﬁnite stent thrombosis occurred in only 2 patients
(0.9%), and late probable stent thrombosis occurred in 1 patient (0.5%).
CONCLUSIONS In a multicenter registration trial representing contemporary technique and EES, favorable proce-
dural success and late-term clinical outcomes support CTO PCI in a patient population with high lesion complexity.
(EXPERT CTO: Evaluation of the XIENCE PRIME LL and XIENCE Nano Everolimus Eluting Coronary Stent Coronary
Stents, Performance, and Technique in Chronic Total Occlusions; NCT01435031) (J Am Coll Cardiol Intv 2015;8:761–9)
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762T he potential merits of chronictotal occlusion (CTO) percutaneouscoronary intervention (PCI) are chal-
lenged by uncertainties related to procedural
outcome, clinical indication, and durability
of late-term vessel patency. Although a
CTO is identiﬁed in approximately 1 in every
3 to 5 coronary angiograms (1,2), the dis-
parity between prevalence and treatment un-
derscores the procedural and clinical
dilemmas presented by these complex le-
sions. Compared with treatment of nonocclu-
sive coronary disease that is associated with
a predictably high likelihood of procedural
success, guidewire recanalization of a CTO
is challenging and remains the principal
cause of failure that, by historical standards,
may approach 40% (3,4). Accordingly, treat-ment decisions (bypass surgery, attempted percuta-
neous revascularization, or continued medical
therapy alone) are commonly derived by default
rather than by decision given the limited therapeutic
options and a less predictable risk/beneﬁt balance for
symptomatic CTO patients.
Unlike catheter-based revascularization of non-
occlusive coronary disease, much of our understand-
ing regarding total occlusions has been further limited
by the fact that there are relatively few studies
with rigorously detailed procedural and clinical re-
sults with contemporary methods and advanced-
generation drug-eluting stents (DES). Until recently,
many of the technologies and techniques promoted
for the treatment of total occlusions were modeled
after devices and methods applied to less complex,
nonocclusive disease, erroneously assuming that the
procedural and clinical outcomes between these
lesion subsets were similar. Moreover, these inves-
tigations were often limited by their retrospective,lth St. Joseph Medical Center, Cardiovascular Center, North Ca
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Recently, considerable progress has been achieved
in CTO PCI, with procedural and clinical outcomes
that represent a clinically signiﬁcant and meaningful
advancement beyond historically discouraging re-
sults. Innovative guidewire methods, including ret-
rograde and dissection re-entry techniques (5,6), in
addition to DES following recanalization (7–11), have
furthered clinical success with safety similar to con-
ventional PCI (12–14). To better characterize the in-
cremental beneﬁt of these advances, we performed a
prospective, multicenter registration trial examining
procedural and clinical outcomes following attemp-
ted CTO PCI with contemporary methods and newer-
generation DES.
METHODS
TRIAL OVERVIEW AND STUDY POPULATION.
EXPERT CTO (Evaluation of the XIENCE Coronary
Stent, Performance, and Technique in Chronic Total
Occlusions) was a prospective, nonrandomized,
multicenter trial evaluating the safety and efﬁcacy of
treatment with everolimus-eluting stents (EES)
(XIENCE V and XIENCE PRIME, Abbott Vascular, Santa
Clara, California) in patients undergoing elective
percutaneous CTO revascularization at 20 hospitals in
the United States (Online Appendix). The study was
approved by the institutional review board at each site.
Eligible patients signed written informed consent
before the interventional procedure. Eligible patients
were$18 years of agewith symptomatic ischemic heart
disease and undergoing clinically driven nonemergent
percutaneous recanalization of a de novo occlusive
coronary lesion, which exhibited Thrombolysis In
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763estimated to be at least 3 months duration by clinical,
angiographic, or electrocardiographic criteria. Patients
who provided consent were considered to be enrolled
upon introduction of the coronary guidewire into the
guiding catheter. Principal angiographic exclusion
criteria were in-stent total occlusions and excessive
vessel angulation that was deemed by the operator as
likely to prohibit stent delivery. There were no re-
strictions regarding lesion length. Clinical exclusion
criteria were recent (<72 h) myocardial infarction (MI),
prior stent placement within the target vessel or any
other vessel within 90 days of the index procedure, or
any general contraindication to the revascularization
procedure and routine pharmacological therapies.
There were no restrictions regarding lesion length or
treatment strategy (e.g., antegrade, retrograde, or
dissection re-entry technique).
STUDY ENDPOINTS AND DEFINITIONS. The primary
endpoint of this study was to evaluate the 1-year
occurrence of major adverse cardiac events (MACE)
(composite of all-cause death, MI, and target lesion
revascularization [TLR]) among patients undergoing
successful CTO PCI, and to compare these events with a
performance goal established from 6 CTO DES trials
reporting at least 1-year MACE (8,15–19). Two analysis
populations were pre-speciﬁed: 1) intent-to-treat, rep-
resenting all enrolled patients for whom recanalization
and pre-dilation of CTO were achieved and EES were
inserted into the guiding catheter; and 2) per protocol,
indicating procedural success with EES with follow-up
data available and no major protocol deviations.
Additional key objectives of this study were to
determine guidewire (HT Progress and HT Pilot
guidewires, Abbott Vascular) and angioplasty (Mini-
Trek, Abbott Vascular) pre-dilation safety and effec-
tiveness. The guidewire endpoint was procedural
success, deﬁned as angiographic conﬁrmation of
guidewire placement in the target vessel true lumen
and absence of in-hospital MACE, and was compared
with a performance goal established from pooled
analysis of 3 studies reporting procedural success in
CTO PCI (20–22). The guidewire endpoint was
analyzed from the initial 138 patients undergoing
attempted CTO PCI. Although a Progress or Pilot
guidewire must have been used during attempted
crossing of the CTO, use of additional guidewires
were permitted. The cohort for the balloon angio-
plasty endpoint included the initial 88 patients with
successful guidewire crossing of the CTO and exam-
ined catheter delivery, performance, and occurrence
of catheter-related angiographic or clinical compli-
cations. Results of this descriptive endpoint have
been previously reported (23).Additional secondary endpoints included the in-
dividual components of the composite endpoint in
addition to target lesion failure (cardiovascular death,
target vessel–related MI, and TLR), device success
(achievement of <50% diameter stenosis with
assigned study stent), procedural success according
to crossing technique, and measures of resource uti-
lization. Clinical safety outcomes included all-cause
and cardiac death, MI, and stent thrombosis (ST)
through 1-year follow-up. Cardiac death was consid-
ered as any fatal event not attributable to a noncar-
diac cause. Both MI and ST were determined per
Academic Research Consortium (ARC) deﬁnition cri-
teria (24). Periprocedural MI was deﬁned as an
increase in creatine kinase (CK) myocardial band
fraction or troponin >3 the upper normal limit
within 48 h of the index procedure. In contrast, MI
per protocol was determined as development of new
pathologic Q waves by electrocardiography, or CK
elevation that exceeded 2 the upper normal limit
in association with elevated CK myocardial band
fraction. An independent clinical events committee
(Harvard Clinical Research Institute, Boston, Massa-
chusetts) adjudicated all clinical endpoints. Coronary
angiograms performed at baseline and follow-up,
if clinically indicated, were reviewed by an inde-
pendent angiographic core laboratory (Beth Israel
Deaconess Angiographic Core Laboratory, Boston,
Massachusetts).
STATISTICAL METHODS. Patients were analyzed for
all safety and efﬁcacy endpoints on the basis of the
intent-to-treat principle as well as per protocol
criteria. Baseline characteristics of study patients
were summarized in terms of frequencies and per-
centages for categorical variables and by mean  SD
for continuous variables. The primary analysis for the
binary outcome against the performance goal was
performed through the binomial distribution. To
develop the performance goal for the primary
endpoint of 1-year MACE, data from 6 CTO DES trials
(8,15–19) were used (Online Table 1). Because some
studies constituting the performance goal utilized a
less conservative deﬁnition of MI not according to
ARC criteria, an upward adjustment in the 1-year
MI rate was necessary. To accommodate for this dif-
ference, data from treatment of long lesions from
additional EES databases (SPIRIT PRIME long lesion
registry, unpublished data, Abbott Vascular, August
2010; and SPIRIT IV long lesion subset, unpublished
data, Abbott Vascular, March 2011) were used as a
surrogate for CTO PCI given that these 2 indications
are representative of similar, complex treatments.
The average difference in 1-year MI between ARC and
TABLE 1 Baseline Patient Clinical and Angiographic
Characteristics of the Everolimus Stent Group (n ¼ 222)
Clinical characteristics
Age, yrs 61.7  10.4
Male 81.1
Diabetes mellitus 40.1
Oral medications 68.5
Insulin requiring 30.3
Hypertension 91.9
History of smoking 26.0
Hyperlipidemia 96.8
Prior myocardial infarction 29.0
Angina class III/IV 59.3
Heart failure class III/IV 2.7
Prior percutaneous revascularization 43.4
Prior coronary bypass surgery 9.9
Number of diseased vessels
1 76.6
2 17.1
3 6.3
Angiographic characteristics
Target vessel
Left anterior descending artery 31.1
Right coronary artery 53.2
Left circumﬂex artery 15.8
TIMI ﬂow grade 0 95.9
Moderate/severe calciﬁcation 49.1
Side branch stenosis $50% 37.2
Reference vessel diameter, mm 2.7  0.4
Lesion length, mm 36.1  18.5
Occlusion length, mm 14.0  10.6
Collateral circulation
Ipsilateral 92.8
Contralateral 92.6
Bridging 86.5
Values are mean  SD or %. Angina and heart failure severity according to Ca-
nadian Cardiovascular Society and New York Heart Association functional classi-
ﬁcation, respectively.
TIMI ¼ Thrombolysis In Myocardial Infarction.
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to the 1-year MACE rates across the pertinent histor-
ical studies. The weighted event rate after the above
adjustment is 14.4%. The ﬁnal performance goal is
set at 24.4% after adding a delta of 10% to account
for variability. This delta was derived from a logistic
regression model from prior EES data between a MACE
endpoint and lesion length. At a single speciﬁc lesion
length (approximately 30 mm), the estimates of the
event rate and its upper limit of the 2-sided 95%
conﬁdence interval (CI) were obtained and utilized
as the assumed true rate and performance goal,
resulting in a difference of 10%.
The test was performed utilizing the binomial dis-
tribution along with the 1-sided conﬁdence limit. Due
to the objective to demonstrate that the true rate is
less than the performance goal, the test is performed
under a 1-sided setup. Assuming an estimated true
rate of 14.4% for the stented population, a 1-sided
alpha level of 0.05, approximately 10% loss to
follow-up, and at least 90% statistical power, an
effective sample size of 180 patients was required to
meet the performance goal. With the assumption that
approximately 72% of CTO procedures would result in
successful guidewire crossing, total enrollment was
therefore estimated to be 250 patients.
Separately, the guidewire endpoint would also be
tested using a performance goal for procedure success
in the absence of in-hospital MACE. Thus, the numer-
ator included all cases of successful guidewire recan-
alization, with the total number of attempted cases
serving as the denominator for a total of 138 patients.
The performance goal of 62.5% for the guidewire
endpoint is derived from 3 historical trials (20–22).
Assuming that the Progress guidewire would achieve a
procedure success rate of 73.3%, which is based on the
best performance from the historical trials, and with a
type I error rate of 0.05 and at least 80% statistical
power, a sample size of 138 patients was required to
meet the performance goal.
All analyses were performed using SAS software
version 8.2 (SAS Institute, Cary, North Carolina).
RESULTS
Among 250 enrolled patients, guidewire recanaliza-
tion of the CTO was achieved in 222 patients (89%).
This patient cohort, therefore, represented the anal-
ysis population for the primary stent-related
endpoint, and baseline clinical and angiographic
characteristics are summarized in Table 1. Overall, the
prevalence of diabetes was 40.1%; prior MI
was documented in 29% of patients; and more
than one-half of patients underwent previouscoronary revascularization. The average lesion and
occlusion lengths were 36.1  18.5 mm and 14.0  10.6
mm, respectively. Bridging collaterals and moder-
ate/severe calciﬁcation were present in the majority
of occlusions. More than one-half of the target lesions
were located in the right coronary artery.
In the entire study population with guidewire
recanalization, procedure success was achieved in
89.6% (198 of 221) of patients using the ARC MI
deﬁnition, and 96.4% (213 of 221) when the protocol
MI deﬁnition was applied (Table 2). Antegrade-only
methods (including dissection re-entry techniques)
were performed in approximately 80% (174 of 221) of
cases followed by combined antegrade/retrograde
and retrograde-only techniques. Procedural success
rates according to guidewire strategy are detailed
in Table 2. For the guidewire endpoint, among a
TABLE 2 Procedural Results for the Everolimus Stent Group
(n ¼ 222)
Stents/lesion 1.95  0.98
Stent length, mm 51.72  27.16
Stent diameter, mm 2.85  0.36
Inﬂation pressure, atm 13.38  3.14
$2 stents implanted 61.7
Overlapping stents 60.8
Minimal luminal diameter, mm
Before procedure
In-lesion 0.01  0.05
After procedure
In-stent 2.32  0.39
In-segment 1.85  0.47
Diameter stenosis, %
Before procedure
In-lesion 99.69  2.13
After procedure
In-stent 12.69  11.11
In-segment 30.76  13.62
Final TIMI ﬂow grade 3 97.7
Clinically signiﬁcant perforation* 0
Procedure time, min 79.9  48.5
Contrast volume, ml 259.0  136.7
Fluoroscopy duration, min 33.6  23.3
Device success
Intention to treat 100.0
Procedural success
ARC MI deﬁnition 89.6
Protocol MI deﬁnition 96.4
Procedure success by guidewire method†
Antegrade 90.2 (174/193)
Retrograde 90.7 (11/12)
Combined antegrade and retrograde 81.3 (13/16)
Values are mean  SD, %, or % (n/N). *Clinically signiﬁcant perforation deﬁned as
any perforation resulting in hemodynamic instability and/or requiring intervention.
†Procedural success reported according to intention-to-treat deﬁnition.
ARC ¼ Academic Research Consortium; MI ¼ myocardial infarction;
TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 3 1-Year Clinical Outcomes for the Everolimus Stent Group
(n ¼ 222)
Death 1.9
MI
ARC deﬁnition 13.9
Protocol deﬁnition 3.4
Clinically driven TLR 6.3
Percutaneous 5.8
Surgical 0.5
MACE
ARC MI deﬁnition 18.5
Protocol MI deﬁnition 10.0
TLF
ARC MI deﬁnition 15.8
Protocol MI deﬁnition 9.1
TVF
ARC MI deﬁnition 16.7
Protocol MI deﬁnition 10.0
Stent thrombosis
Acute 0
Subacute
Deﬁnite 0.9
Probable 0
Late
Deﬁnite 0
Probable 0.5
Values are %.
MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; TLF ¼ target
lesion failure; TLR ¼ target lesion revascularization; TVF ¼ target vessel failure;
other abbreviations as in Table 2.
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765pre-speciﬁed cohort of 138 initial patients undergo-
ing attempted CTO PCI, successful guidewire
crossing was achieved in 89.9% of patients.
Compared with the guidewire performance goal
endpoint of 62.5% for procedural success, statistical
superiority was achieved by both primary (ARC:
79%; 95% CI: 71.2 to 85.5; p < 0.0001) and per-
protocol analyses (87.7%; 95% CI: 81.0 to 92.7; p <
0.0001). The average number of guidewires per case
was 5.7 (range 1 to 18).
All patients with successful guidewire recanaliza-
tion received treatment with EES. At 1 year, MACE
occurred in 18.5% of patients (n ¼ 222; upper 95%
conﬁdence limit: 23.4%; p ¼ 0.025 compared with
pre-speciﬁed performance goal) by ITT analysis, and
8.2% of patients by per-protocol analysis (n ¼ 183;upper 95% conﬁdence limit: 12.3%; p < 0.0001)
(Table 3). The difference in endpoints was princi-
pally driven by assessment and deﬁnition of MI
(13.9% by ITT and 3.4% per protocol). Elevation of
CK myocardial band >10 the upper normal limit
occurred in only 1.8% (4 of 220) of patients
(Figure 1).
At 1 year, clinically driven target lesion revascu-
larization was 6.3% (13 of 207), and cardiac death
occurred in 1.9% (2 of 208) of patients (Table 3). Def-
inite subacute ST was identiﬁed in 2 patients (0.9%),
with no deﬁnite events observed after 30 days. Late
probable ST was identiﬁed in 1 patient (0.5%).
Notably, adherence to dual antiplatelet therapy at 1
year was 53.9%. All deﬁnite and probable ST events
occurred while patients reported compliance with
dual antiplatelet therapy.
DISCUSSION
In a multicenter registration trial representing con-
temporary technique, broad operator experience, and
newer-generation EES, favorable procedural success
and late-term clinical outcomes support CTO PCI
FIGURE 1 MI According to Biomarker Elevation*
Determination of myocardial infarction (MI) according to creatine kinase-myocardial band
elevation. *2MI events diagnosed by troponin only. ULN ¼ upper limit of normal.
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Speciﬁcally, CTO PCI employing advanced guidewire
technique, dissection re-entry methods, and ante-
grade and retrograde strategies was associated with
successful recanalization that approached 90%, rep-
resenting a substantial improvement above historical
standards. Further, despite high lesion complexity
and extensive stent length, treatment with EES was
associated with rates of repeat revascularization and
ST similar to outcomes observed in less complex
disease and clinical indications. These ﬁndings chal-
lenge common perceptions in CTO PCI regarding
likelihood of procedural success and durability of
late-term vessel patency.
Against the background of outcomes data indi-
cating beneﬁt following CTO revascularization and
the successes of DES in maintaining target vessel
patency is the stark reality that any potential
advantage of CTO PCI is handicapped from the outset
by the commonality of procedural failure. As an
example, despite the frequency of attempted CTO PCI
within the SYNTAX (Synergy Between Percutaneous
Coronary Intervention with Taxus and Cardiac Sur-
gery) trial, procedural success was only achieved
in 49% of lesions (3). As a prospective, multicenter
trial, the present study represents 1 of the most
comprehensive examinations of procedural methods,
resource utilization, and outcomes in contemporary
CTO PCI, representing a generally unrestricted CTO
patient population and broad operator experienceand technique. Despite extensive lesion length and
complexity, a high level of procedural success was
achieved through application of antegrade and ret-
rograde guidewire maneuvers and with favorable
safety. Indeed, the procedural success endpoint was
most inﬂuenced by the inclusion and deﬁnition of
MI; when periprocedural MI was adjudicated ac-
cording to the conservative ARC criteria (24), its fre-
quency was more common than guidewire failure.
Alternatively, nearly all MI events were characterized
by biomarker elevation that fell below thresholds
proposed as a clinically relevant standard (25), and its
occurrence did not translate to adverse events
through 1-year post-revascularization. Also, given
that the pooled analyses of previous CTO studies to
establish both the guidewire and stent performance
goals were based on broader and less conservative
deﬁnitions of MI than in the current study, these
historical endpoints represented an even more con-
servative comparison that might have biased against
the study cohort.
Apart from a variety of novel but often disap-
pointing technologies for crossing occluded coronary
segments, specialized coronary guidewires remain
the mainstay instrument for CTO recanalization.
Although CTO-speciﬁc guidewire technology itself
has evolved considerably, a more revolutionary
advancement has related to the technical skills and
strategies regarding how these tools are used. Over-
all, guidewire crossing of the occlusion was dem-
onstrated in 89% of enrolled patients, and in a
pre-speciﬁed subgroup powered for comparison
with prior CTO studies that largely represented more
conventional antegrade guidewire methods (20–22),
application of antegrade, retrograde, and dissection
re-entry techniques resulted in statistically and clin-
ically superior rates of procedural success. An
average of 6 guidewires/case reﬂected both lesion
complexity and technique, in the latter instance
leveraging different guidewire features for differing
aspects of lesion crossing (e.g., proximal cap pene-
tration, traversing body of occlusion, distal lumen re-
entry).
Similar to coronary guidewires, no previous study
has been designed and completed as a registration
trial with Food and Drug Administration oversight for
newer-generation DES approval in an expanded
indication of CTO percutaneous revascularization. In
general, our understanding of procedural and clinical
effectiveness of DES following CTO revascularization
has been limited by the routine exclusion or under-
representation of such patients in most major
interventional cardiology clinical trials. Further, un-
like the widespread evaluation of DES beyond
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767approved patient and lesion indications, relatively
few investigations have been performed to support
the clinical beneﬁt of DES in total occlusion revascu-
larization, especially with more recent-generation
DES that may convey clinical beneﬁt over ﬁrst-
generation DES. This latter issue is especially rele-
vant given that failure to achieve or sustain patency
after CTO recanalization has been associated with
impairment in regional and global left ventricular
systolic function, recurrent angina and target vessel
revascularization, and a greater need for late bypass
surgery (26).
Among patients enrolled in this study, lesion and
stent length assessed by an independent core labo-
ratory were among the most extensive described in
contemporary DES reports, and to our knowledge,
more than any other DES indication approval study.
Despite this complexity, 1-year outcomes of TLR
(6.3%) and deﬁnite ST (1%) were comparable with
observations of EES in less complex, nonocclusive
coronary disease. Further, compared with MACE
rates derived from a pooled analysis of ﬁrst-
generation CTO DES trials, treatment with EES was
associated with a signiﬁcant reduction in adverse
events at 1 year. In part attributed to thinner strut
design, enhanced stent geometry, and polymer
biocompatibility, these latter ﬁndings are consistent
with prior comparative studies demonstrating the
superiority of EES over ﬁrst-generation DES in simple
to moderate complexity disease (27–30). Depending
upon endpoint deﬁnitions as previously described,
the relative reduction in MACE ranged from one- to
two-thirds with newer-generation EES. Notably, the
low ST rate is observed despite approximately one-
half of patients remaining adherent to dual anti-
platelet therapy over this time period. Compared
with prior studies of EES in CTO revascularization,
outcomes in this study were similar if not improved;
in prior studies of EES in CTO PCI (9,10,31), rates of
repeat revascularization ranged from 8% to 11%, and
ST was inconsistently reported. Despite similar
lesion and stent length in the present study, rates
of repeat revascularization were somewhat lower,
likely due to the absence of mandatory angiographic
surveillance.
STUDY LIMITATIONS. In the absence of randomiza-
tion, a limitation to this analysis is that the possibility
that measured or unmeasured confounders may
have affected the comparison of these results with a
performance goal derived from a pooled analysis
of prior CTO DES trials cannot be excluded. As
previously described, however, application of aless-conservative deﬁnition of MI would be expected
to bias against the EES cohort, even despite statistical
adjustment for differences in MI ascertainment. In
addition, this study did not include mandatory
angiographic surveillance that may inform rates of
restenosis and reocclusion and also exaggerate esti-
mates of repeat revascularization. Angiographic out-
comes with EES in CTO PCI have been previously
described. Instead, the intent of the current trial was
to systematically detail patient-oriented procedural
and clinical outcomes. Also regarding procedural
outcomes, in comparison with some prior studies of
occluded arteries, all CTOs were estimated as
“chronic,” a characteristic that historically has been
negatively related to technical success of recanaliza-
tion, reﬂects lesion complexity, and underscores the
capabilities of CTO PCI using contemporary methods
and technologies.
CONCLUSIONS
In a multicenter registration trial representing
contemporary technique, broad operator experience,
and newer-generation DES, favorable procedural suc-
cess and late-term clinical outcomes support CTO PCI
in a patient population with high lesion complexity.
Speciﬁcally, CTO PCI employing an advanced proce-
dural technique and newer-generation DES was asso-
ciated with favorably high rates of both procedural and
1-year clinical success, representing a substantial
improvement above historical benchmarks. Despite
high lesion complexity and extensive stent length,
treatment with EES was associated with rates of repeat
revascularization and ST similar to outcomes observed
in less complex disease and clinical indications. These
results challenge common perceptions in CTO PCI
regarding the likelihood of procedural effectiveness
and durability of late-term clinical success. Dedicated
long-term follow-up will further clarify the late safety
and efﬁcacy of EES treatment in this complex lesion
subset. Even so, the results suggest that treatment
with EES should be favored for percutaneous revas-
cularization in chronically occluded native coronary
arteries.
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PERSPECTIVES
WHAT IS KNOWN? CTO PCI has been associated with
reduced angina, improved left ventricular function, and
enhanced survival. However, technical challenges and
uncertainties regarding clinical outcome challenge more
widespread consideration of PCI for this indication.
WHAT IS NEW? Application of contemporary proce-
dural technique and newer-generation DES suggest
improved early and late-term outcomes among patients
undergoing attempted CTO PCI. Among operators with
broad CTO experience, PCI of total coronary occlusions is
associated with high procedural success and favorable
clinical outcomes that are similar to those observed in
less-complex PCI populations.
WHAT IS NEXT? CTO PCI employing advanced proce-
dural technique and newer-generation DES represents a
substantial improvement above historical benchmarks
and should be considered when clinically appropriate.
These results challenge common perceptions of CTO PCI
regarding the likelihood of procedural effectiveness and
durability of late-term clinical success.
Kandzari et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5
The EXPERT CTO Trial M A Y 2 0 1 5 : 7 6 1 – 9
768RE F E RENCE S1. Fefer P, Knudtson ML, Cheema AN, et al. Cur-
rent perspectives on coronary chronic total oc-
clusions: the Canadian Multicenter Chronic Total
Occlusions Registry. J Am Coll Cardiol 2012;59:
991–7.
2. Christofferson RD, Lehmann KG, Martin GV,
Every N, Caldwell JH, Kapadia SR. Effect of chronic
total occlusion on treatment strategy. Am J Car-
diol 2005;95:1088–91.
3. Farooq V, Serruys PW, Garcia-Garcia HM, et al.
The negative impact of incomplete angiographic
revascularization on clinical outcomes and its as-
sociation with total occlusions: the SYNTAX
(Synergy Between Percutaneous Coronary Inter-
vention with Taxus and Cardiac Surgery) Trial.
J Am Coll Cardiol 2013;61:282–94.
4. Grantham JA, Marso SP, Spertus J, House J,
Holmes DR Jr., Rutherford BD. Chronic total oc-
clusion angioplasty in the United States. J Am Coll
Cardiol Intv 2009;2:479–86.
5. Joyal D, Thompson CA, Grantham JA, Buller CEH,
Rinfret S. The retrograde technique for recanaliza-
tion of chronic total occlusions: a step-by-step
approach. J Am Coll Cardiol Intv 2012;5:1–11.
6. Brilakis ES, Grantham JA, Rinfret S, et al.
A percutaneous treatment algorithm for crossing
coronary chronic total occlusions. J Am Coll Car-
diol Intv 2012;5:367–79.
7. Kandzari DE, Rao SV, Moses JW, et al. Clinical
and angiographic outcomes with sirolimus-eluting
stents in total coronary occlusions: the ACROSS/
TOSCA-4 (Approaches to Chronic Occlusions With
Sirolimus-Eluting Stents/Total Occlusion Study of
Coronary Arteries-4) trial. J Am Coll Cardiol Intv
2009;2:97–106.
8. Suttorp MJ, Laarman GJ, Rahel BM, et al. Pri-
mary stenting of totally occluded native coronary
arteries II (PRISON II): a randomized comparison of
bare metal stent implantation with sirolimus-
eluting stent implantation for the treatment oftotal coronary occlusions. Circulation 2006;114:
921–8.
9. Moreno R, García E, Teles R, et al., for the
CIBELES Investigators. Randomized comparison of
sirolimus-eluting and everolimus-eluting coronary
stents in the treatment of total coronary occlu-
sions: results from the chronic coronary occlusion
treated by everolimus-eluting stent randomized
trial. Circ Cardiovasc Interv 2013;6:21–8.
10. Valenti R, Vergara R, Migliorini A, et al. Pre-
dictors of reocclusion after successful drug-
eluting stent-supported percutaneous coronary
intervention of chronic total occlusion. J Am Coll
Cardiol 2013;61:545–50.
11. Colmenarez HJ, Escaned J, Fernandez C, et al.
Efﬁcacy and safety of drug-eluting stents in
chronic total coronary occlusion recanalization: a
systematic review and meta-analysis. J Am Coll
Cardiol 2010;55:1854–66.
12. Patel VG, Brayton KM, Tamayo A, et al. Inci-
dence of angiographic success and procedural
complications in patients undergoing percuta-
neous coronary chronic total occlusion in-
terventions: a weighted meta-analysis of 18,061
patients from 65 studies. J Am Coll Cardiol Intv
2013;6:128–36.
13. Karmpaliotis D, Michael T, Brilakis ES, et al.
Retrograde coronary chronic total occlusion
revascularization: procedural and in-hospital pro-
cedural outcomes from a multicenter registry in
the United States. J Am Coll Cardiol Intv 2012;5:
1273–9.
14. Rathore S, Matsuo H, Terashima M, et al.
Procedural and in-hospital outcomes after percu-
taneous coronary intervention for chronic total
occlusions of coronary arteries 2002 to 2008:
impact of novel guidewire techniques. J Am Coll
Cardiol Intv 2009;2:489–97.
15. Ge L, Iakovou I, Cosgrave J, et al. Immediate
and mid-term outcomes of sirolimus-eluting stentimplantation for chronic total occlusions. Eur
Heart J 2005;26:1056–62.
16. Werner G, Krack A, Schwarz G, Prochnau D,
Betge S, Figulla HR. Prevention of lesion recur-
rence in chronic total coronary occlusions by
paclitaxel-eluting stents. J Am Coll Cardiol 2004;
44:2301–6.
17. Migliorini A, et al. Drug-eluting stents sup-
ported percutaneous coronary intervention for
chronic total coronary occlusions. Cathet Car-
diovasc Intervent 2006;67:344–8.
18. Bullesfeld L, Gerckens U, Mueller R,
Schmidt T, Grube E. Polymer-based paclitaxel-
eluting stent for treatment of chronic total oc-
clusions of native coronaries: results of a TAXUS
CTO registry. Cathet Cardiovasc Intervent 2005;
66:173–7.
19. De Felice F, Fiorilli R, Parma A, et al. Clinical
outcome of patients with chronic total occlusions
treated with drug-eluting stents. Int J Cardiol
2009;132:337–41.
20. Prasad A, Rihal CS, Lennon RJ, Wiste HJ,
Singh M, Holmes DR. Trends in outcomes after
percutaneous coronary intervention for chronic
total occlusions: a 25-year experience from the
Mayo Clinic. J Am Coll Cardiol 2007;49:1611–8.
21. Suero JA, Marso SP, Jones PG, et al. Procedural
outcomes and long-term survival among patients
undergoing percutaneous coronary intervention of
a chronic total occlusion in native coronary ar-
teries: a 20-year experience. J Am Coll Cardiol
2001;38:409–14.
22. Olivari Z, Rubartelli P, Piscione F, et al. Im-
mediate results and one-year clinical outcome
after percutaneous coronary interventions in
chronic total occlusions: data from a multicenter,
prospective, observational study (TOAST-GISE).
J Am Coll Cardiol 2003;41:1672–8.
23. Kini AS, Karmpaliotis D, Tummala PE, et al.
MINI TREK Coronary dilatation catheter in
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5 Kandzari et al.
M A Y 2 0 1 5 : 7 6 1 – 9 The EXPERT CTO Trial
769predilatation of chronic total occlusion (CTO)
lesions: results from the EXPERT CTO multi-
center clinical trial. Cathet Cardiovasc Intervent
2013;81:S48.
24. Cutlip DE, Windecker S, Mehran R, et al., on
behalf of the Academic Research Consortium. Clinical
endpoints in coronary stent trials: a case for stan-
dardized deﬁnitions. Circulation 2007;115:2344–51.
25. Moussa ID, Klein LW, ShahB, et al. Consideration
of a new deﬁnition of clinically relevant myocardial
infarctionafter coronary revascularization: anexpert
consensus document from the Society for Cardio-
vascular Angiography and Interventions. Cathet
Cardiovasc Intervent 2014;83:27–36.
26. Stone GE, Kandzari DE, Mehran R, et al.
Percutaneous recanalization of chronically oc-
cluded coronary arteries: a consensus document:
part I. Circulation 2005;112:2364–72.27. Bangalore S, Kumar S, Fusaro M, et al. Short-
and long-term outcomes with drug-eluting and
bare-metal coronary stents: a mixed-treatment
comparison analysis of 117 762 patient-years of
follow-up from randomized trials. Circulation
2012;125:2873–91.
28. Baber U, Mehran R, Sharma SK, et al. Impact of
the everolimus-eluting stent on stent thrombosis:
a meta-analysis of 13 randomized trials. J Am Coll
Cardiol 2011;58:1569–77.
29. Kang SH, Park KW, Kang DY, et al. Biodegrad-
able-polymer drug-eluting stents versus bare metal
stents versus durable-polymer drug-eluting stents.
A systematic review and Bayesian approach network
meta-analysis. Eur Heart J 2014;35:1147–58.
30. Navarese EP, Tandjung K, Claessen B, et al.
Safety and efﬁcacy outcomes of ﬁrst and second
generation durable polymer drug eluting stentsand biodegradable polymer biolimus eluting
stents in clinical practice: comprehensive network
meta-analysis. BMJ 2013;347:f6530.
31. Valenti R, Vergara R, Migliorini A, et al.
Comparison of everolimus-eluting stent with
paclitaxel-eluting stent in long chronic total oc-
clusions. Am J Cardiol 2011;107:1768–71.KEY WORDS chronic total occlusion,
drug-eluting stent, everolimus,
percutaneous coronary intervention
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